John Quisel Biography and Net Worth

CEO of Disc Medicine

John is the CEO of Disc Medicine. Previously, John was Chief Business Officer at Acceleron Pharma, where he spent more than thirteen years helping to build the company from a privately-held startup to a public biotech (acquired by Merck & Co. for over $11 billion in 2021). At Acceleron, John served in various roles including General Counsel, Senior Vice President of Corporate Development and finally Executive Vice President and Chief Business Officer. John led the in-licensing of sotatercept for pulmonary hypertension from Bristol-Myers Squibb and helped negotiate the collaboration agreement governing the development and commercialization of luspatercept (now marketed as Reblozyl®️). Prior to Acceleron, John worked at the law firms of Ropes & Gray and Foley Hoag. He received his undergraduate degree from Harvard College, summa cum laude, MSc from Stanford University, PhD from MIT in Biological Sciences, and JD from Harvard Law School.

What is John D. Quisel's net worth?: The estimated net worth of John D. Quisel is at least $6.81 million as of February 18th, 2025. Quisel owns 154,828 shares of Disc Medicine stock worth more than $6,813,980 as of April 23rd. This net worth evaluation does not reflect any other investments that Quisel may own. Additionally, Quisel receives an annual salary of $903,460.00 as CEO at Disc Medicine. Learn More about John D. Quisel's net worth.
How old is John D. Quisel?: Quisel is currently 53 years old. There are 7 older executives and no younger executives at Disc Medicine. Learn More on John D. Quisel's age.
What is John D. Quisel's salary?: As the CEO of Disc Medicine, Inc., Quisel earns $903,460.00 per year. Learn More on John D. Quisel's salary.
How do I contact John D. Quisel?: The corporate mailing address for Quisel and other Disc Medicine executives is 297 Boston Post Road #248, Wayland MA, 01778. Disc Medicine can also be reached via phone at 617-401-4400 and via email at ir@geminitherapeutics.com. Learn More on John D. Quisel's contact information.
Has John D. Quisel been buying or selling shares of Disc Medicine?: John D. Quisel has not been actively trading shares of Disc Medicine in the last ninety days. Most recently, John D. Quisel sold 5,574 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a transaction totalling $304,228.92. Following the completion of the sale, the chief executive officer now directly owns 154,828 shares of the company's stock, valued at $8,450,512.24. Learn More on John D. Quisel's trading history.
Who are Disc Medicine's active insiders?: Disc Medicine's insider roster includes Mona Ashiya (Director), Kevin Bitterman (Director), Joanne Bryce (CFO), Jean Franchi (CFO), Rahul Khara (Insider), Brian Macdonald (Insider), John Quisel (CEO), William Savage (Insider), Pamela Stephenson (Insider), William White (Director), and Jonathan Yu (COO). Learn More on Disc Medicine's active insiders.
Are insiders buying or selling shares of Disc Medicine?: During the last year, insiders at the sold shares 21 times. They sold a total of 447,850 shares worth more than $25,068,128.17. The most recent insider tranaction occured on March, 24th when Director Mona Ashiya sold 5,738 shares worth more than $310,483.18. Insiders at Disc Medicine own 4.2% of the company. Learn More about insider trades at Disc Medicine.
Information on this page was last updated on 3/24/2025.

John D. Quisel Insider Trading History at Disc Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2025	Sell	5,574	$54.58	$304,228.92	154,828
12/30/2024	Sell	13,012	$61.95	$806,093.40	72,065
12/23/2024	Sell	19,820	$63.14	$1,251,434.80	72,065
12/16/2024	Sell	12,791	$66.01	$844,333.91	72,065

John D. Quisel Buying and Selling Activity at Disc Medicine

Disc Medicine Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $44.01

$42.93

$45.39

50 Day Range

MA: $49.07

$34.28

$56.92

2 Week Range

Now: $44.01

$25.64

$68.73

Volume

455,734 shs

Average Volume

345,482 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

John Quisel Biography and Net Worth

What is John D. Quisel's net worth?

How old is John D. Quisel?

What is John D. Quisel's salary?

How do I contact John D. Quisel?

Has John D. Quisel been buying or selling shares of Disc Medicine?

Who are Disc Medicine's active insiders?

Are insiders buying or selling shares of Disc Medicine?